SG3 Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

SG3 Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9,000	Closed	-$38.9K	–	28
2022 Q4	$38.9K	Hold	9,000	–	–	0.01%	190
2022 Q3	$67.7K	Hold	9,000	–	–	0.01%	242
2022 Q2	$90K	Sell	9,000 -162,800	-95%	-$1.82M	0.01%	326
2022 Q1	$2.13M	Sell	171,800 -11,000	-6%	-$170K	0.06%	290
2021 Q4	$4.18M	Buy	182,800 +99,800	+120%	+$2.36M	0.09%	211
2021 Q3	$1.84M	Buy	83,000 +74,000	+822%	+$1.17M	0.06%	325
2021 Q2	$117K	Sell	9,000 -187,000	-95%	-$2.38M	﹤0.01%	883
2021 Q1	$2.54M	Sell	196,000 -169,500	-46%	-$2.46M	0.06%	340
2020 Q4	$5.05M	Buy	365,500 +235,500	+181%	+$3.43M	0.1%	190
2020 Q3	$1.92M	Buy	130,000 +129,900	+129,900%	+$1.88M	0.07%	282
2020 Q2	$2K	Buy	+100	New	+$1.6K	﹤0.01%	596

Other funds holding AUPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SG3 Management's AUPH Position: Q1 2022 in Review

SG3 Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2022, closing a stake of 42,500 shares — an estimated $657K sold.

SG3 Management first reported a position in AUPH in Q2 2020 and held it in 6 quarters. The position peaked at $1.5M in Q3 2021. 184 funds tracked by Wall St. Rank hold AUPH as of Q1 2022.

SG3 Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 42,500 Aurinia Pharmaceuticals shares in Q1 2022, an estimated $657K.
SG3 Management first reported a position in Aurinia Pharmaceuticals in Q2 2020 and held it in 6 quarters.
SG3 Management's Aurinia Pharmaceuticals position peaked at $1.5M in Q3 2021.
184 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.